Foundation Medicine, Relay Therapeutics to collaborate

2022 04 22 17 54 4420 Business Handshake Man 400

Foundation Medicine and Relay Therapeutics said Monday that they plan to collaborate on developing the FoundationOne CDx as a companion diagnostic tool for use with Relay's FGFR2 inhibitor, RLY-4008l.

RLY-4008 is a work-in-progress oral small-molecule inhibitor of FGFR2, which is part of a set of proteins that can mutate into diseases such as cholangiocarcinoma, according to Foundation Medicine. Under the collaboration, FoundationOne CDx would be used to help clinicians identify patients with FGFR2 mutations and select those who could benefit from treatment with RLY-4008.

On September 11 at the European Society of Medical Oncology (ESMO) 2022 meeting in Paris, Relay presented clinical data that suggests that RLY-4008 is effective in killing FGFR2-dependent cancer cells, Foundation Medicine said.

Page 1 of 12
Next Page